Composition, form of production and packaging
The solution for the / m administration is transparent, from light yellow to yellow.
1 ml
carboximide 150 mg
Excipients: citric acid, sodium hydroxide, sodium chloride, disodium edetate (Trilon B), water d / u.
1 ml - ampoules (5) - packings the cellular contour (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Carboxyme belongs to the group of cholinesterase reactivators of the pyridinium series. It has a pronounced antidote effect in the treatment of lesions with organophosphorus compounds (OPC). Timely application of carboxyme significantly accelerates the recovery of cholinesterase activity, inhibited by FOS. Also has a positive effect on some other manifestations of poisoning (reduces bronchospasm, motor disorders, etc.). Carboxyme has low toxicity, almost no cholinolytic action.
INDICATIONS
- appearance of initial signs of poisoning FOS (agitation, miosis, drooling, etc.) in the provision of medical care, starting with the health center;
- Detection of a person who is under observation after being in the focus of infection, reduce the activity of cholinesterase.
Carboxyme is used against the background of antidote (atropine, Athens, P-10M) and other agents used in the treatment of poisonings of OP. After the introduction of the therapeutic antidote, carboxyme is administered after 1-2 hours.
DOSING MODE
Intramuscularly 1 ml. The total dose of carboxymethylate used in the provision of care depends on the severity of the lesion.
For lesions of WCF of mild degree (anxiety, miosis, drooling, sweating) after administration of preparations of holinolitic type of action, carboxyme is used in one therapeutic dose. In some cases, repeated administration of the drug in the same dose is possible.
For lesions of FOS of moderate severity (exacerbation, myofibrillation, bronchospasm, cyanosis, tachycardia, less often bradycardia), as a rule, two applications of carboxime in one treatment dose with an interval of 2-3 hours will be required.
For lesions of WCF of a serious degree (convulsions, coma, respiratory and cardiovascular insufficiency), the dose of carboxyme can be increased to 3-4 ml. This dose is given by 1 ml of the drug at intervals of 1-2 hours. Treatment of affected OPC with the use of carboxyme in all cases is carried out with a systematic
control of cholinesterase activity.
SIDE EFFECT
In the recommended dose, carboxymethylsulfate does not cause side effects. Nevertheless, with the use of large doses of carboxymus, there may be a deterioration in well-being, muscle weakness, dizziness, headache, nausea, tachycardia. Perhaps the emergence of transient paresthesia (mainly in the face area). On the ECG, there may be phenomena of intracardiac conduction disturbance and an increase in the systolic index. These phenomena soon pass and do not require additional treatment.
CONTRAINDICATIONS
- In the presence of symptoms of intoxication, OPC contraindications for the use of carboxymethacid.
TERMS OF RELEASE FROM PHARMACY
On prescription.
TERMS AND CONDITIONS OF STORAGE
List B. Store in a dark place out of the reach of children, at a temperature not exceeding 20 В° РЎ. Shelf life - 2 years.
